LSD increases sleep duration the night after microdosing.

The contemporary rise in microdosing psychedelic drugs involves the consumption of substances at levels far below the threshold required to induce hallucinations or perceptual distortions. Prior research has shown that Lysergic Acid Diethylamide (LSD) interacts with serotonergic pathways, which are fundamentally involved in the regulation of both mood and the sleep-wake cycle. While anecdotal reports suggest that these sub-perceptual doses can enhance focus and emotional well-being, the scientific community lacks objective data regarding their systemic physiological effects. Sleep serves as a foundational indicator of neurological health, yet its relationship with chronic, low-dose psychedelic use remains largely unexplored in controlled clinical settings. The absence of longitudinal studies using wearable technology has left a significant gap in our understanding of how these substances influence nocturnal recovery. Understanding the interaction between LSD and sleep architecture is essential for assessing the long-term safety of this increasingly common lifestyle practice. This absence of evidence motivated the current investigation into the objective sleep metrics of healthy individuals following a structured six-week microdosing protocol.

This investigation evaluates the impact of repeated low-dose LSD administration on objective sleep parameters in a healthy cohort of adult males. Researchers sought to determine if a 10 µg dose, taken every third day, induces measurable changes in total sleep time or the distribution of specific sleep stages. The study addresses the lack of longitudinal data regarding the safety and physiological consequences of long-term microdosing practices within the general population. Investigators aimed to distinguish between the immediate effects on the day of administration and the delayed effects occurring the subsequent night to map the temporal influence of the drug. The trial provides a rigorous, double-blind, placebo-controlled assessment to eliminate the subjective biases and expectancy effects often found in self-reported microdosing surveys. By utilizing objective tracking devices, the team intended to capture precise data on sleep duration and physical activity levels across thousands of individual nights. The primary objective was to establish whether sub-hallucinogenic doses of LSD modify the physiological sleep requirements of healthy volunteers over a six-week period.

A Phase 1 randomized controlled trial enrolled 80 healthy adult male volunteers to undergo a comprehensive six-week experimental course of treatment. Participants self-administered either a 10 µg dose of LSD or a matching placebo every third day throughout the study duration. The research team utilized a commercially available sleep/activity tracker to collect continuous, high-resolution physiological data from each subject in their home environment. This wearable technology monitored movement patterns and heart rate variability to estimate total sleep duration and the proportion of time spent in various sleep stages. Statistical analysis encompassed 3231 nights of sleep data, allowing for a robust comparison between the experimental LSD group and the control placebo group. The trial was registered with the Australian New Zealand Clinical Trials Registry and followed a double-blind protocol to ensure the integrity of the objective measurements. Researchers specifically analyzed the data to isolate the effects on the dosing day versus the effects on the subsequent night to identify any delayed physiological responses.

Data analysis revealed that participants in the LSD group experienced an extra 24.3 minutes of sleep per night on the evening following a microdose. The 95% Confidence Interval for this increase ranged from 10.3 to 38.3 minutes, indicating a statistically significant deviation from the sleep patterns observed in the placebo group. No significant reductions or increases in sleep duration occurred on the actual day the dose was administered, suggesting the drug does not immediately disrupt or promote sleep. The proportion of time spent in various sleep stages, including deep sleep and REM sleep, remained consistent between the two groups throughout the six-week trial. Physical activity levels showed no measurable changes, which implies that the increased sleep duration was not a secondary effect of altered daytime exertion or fatigue. The results remained consistent across the 3231 nights of data collected, providing a high degree of confidence in the observed modification of sleep requirements. These clinically significant changes in objective measurements are difficult to explain as a placebo effect, given the consistency and magnitude of the sleep duration increase.

These findings demonstrate a clear modification of physiological sleep requirements in healthy male volunteers following a structured LSD microdosing regimen. The observed increase in sleep duration suggests that low doses of LSD may exert a delayed influence on the neural mechanisms governing sleep homeostasis and recovery. Because the changes were captured through objective wearable technology, the results provide a more reliable assessment of microdosing than previous studies relying on subjective self-reports. Future research should investigate whether these sleep changes correlate with the cognitive or emotional benefits frequently reported by microdosing practitioners in various community settings. The study establishes a foundational baseline for understanding the safety profile and physiological footprint of LSD when used at sub-hallucinogenic levels. Clinicians and researchers must consider these sleep modifications when evaluating the therapeutic potential or potential side effects of psychedelic microdosing in broader populations. The results highlight the importance of using objective physiological monitoring to uncover the subtle but significant biological impacts of low-dose psychedelic substances.